Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Murder, Insanity, and Medical Expert Witnesses
ARch Neurol 49:608-611, Ciccone,J.R., 1992
Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease
Arch Neurol 48:1141-1143, Chen,J.,et al, 1991
A Pilot Study of Haloperidol Treatment of Psychosis and Behavioral Disturbance in Alzheimer's Disease
Arch Neurol 46:854-857, Devanand,D.P.,et al, 1989
Psychotic Symptoms in Alzheimer's Disease
Editorial, Lancet 2:1193-11941989., , 1989
Predictors of Disease Course in Patients with Probable Alzheimer's Disease
Neurol 37:1649-1653, Stern,Y.,et al, 1987
Capgras Syndrome:A Reduplicative Phenomenon
Neurol 29:334-339, Alexander,M.P.,et al, 1979